Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Sales and Divestitures (2016 - 2021)

ImmunityBio (IBRX) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $336084.0 as the latest value for Q2 2021.

  • Quarterly Gains from Sales and Divestitures fell 39.88% to $336084.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $336084.0 through Jun 2021, down 39.88% year-over-year, with the annual reading at $648336.0 for FY2020, 64.11% up from the prior year.
  • Gains from Sales and Divestitures for Q2 2021 was $336084.0 at ImmunityBio, up from $235725.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $648336.0 in Q4 2020, with the low at $6625.0 in Q1 2017.
  • Average Gains from Sales and Divestitures over 5 years is $234234.9, with a median of $172330.0 recorded in 2018.
  • The sharpest move saw Gains from Sales and Divestitures crashed 93.04% in 2017, then surged 959.62% in 2018.
  • Over 5 years, Gains from Sales and Divestitures stood at $244209.0 in 2017, then dropped by 29.43% to $172330.0 in 2018, then surged by 129.24% to $395051.0 in 2019, then skyrocketed by 64.11% to $648336.0 in 2020, then crashed by 48.16% to $336084.0 in 2021.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $336084.0, $235725.0, and $648336.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.